ArticleCardiovascular and interventional radiology2021
Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?
Article in Cardiovascular and interventional radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.European journal of nuclear medicine and molecular imaging · 2023Trial
- Personalized lung dosimetry evaluated byJapanese journal of radiology · 2026Article
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Q.Liver software for the planning of treatment of liver cancer via transarterial radioembolization with yttrium-90 resin microspheres based on single-photon emission computed tomography-computed tomography.Quantitative imaging in medicine and surgery · 2026Article
- Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective.Korean journal of radiology · 2025Review
- An international phantom study of inter-site variability in Technetium-99m image quantification: analyses from the TARGET radioembolization study.EJNMMI physics · 2024Article
- Implications of lung shunt fraction calculation discrepancy in Yttrium-90 radioembolization treatment from 2D planar vs 3D single photon emission CT imaging.BJR case reports · 2024Article
- Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [Cardiovascular and interventional radiology · 2024Article
- MIRD Pamphlet No. 29: MIRDy90-AJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips.Seminars in interventional radiology · 2024Review
- Voxel-S-value methods adapted to heterogeneous media for quantitative Y-90 microsphere radioembolization dosimetry.Zeitschrift fur medizinische Physik · 2023Article
- Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing HepaticCardiovascular and interventional radiology · 2022Article
- Prediction of Lung Shunt Fraction for Yttrium-90 Treatment of Hepatic Tumors Using Dynamic Contrast Enhanced MRI with Quantitative Perfusion Processing.Tomography (Ann Arbor, Mich.) · 2022Article
- Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies.Oncology and therapy · 2021Review
- Role of SIRT in Patients With Hepatocellular Carcinoma: Current Clinical Indications and Future Perspectives.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare lung shunt fraction (LSF) prior to Y-90 radioembolization calculated using planar imaging versus SPECT/CT in patients with hepatocellular carcinoma (HCC).
methodsA single institution retrospective analysis of technetium-99m macroaggregated albumin (Tc-99m MAA) LSF studies for 293 consecutive patients with HCC between 2013 and 2018 was performed. LSF using planar imaging (PLSF) was compared to retrospectively calculated LSF using SPECT/CT (SLSF) via semiautomated segmentation using MIM v.6.9. Sub-analyses of patients were performed based on PLSF range, tumor size, BCLC stage, and Child-Pugh (C-P) score. Mean LSF absolute discrepancy between sub-groups was analyzed. Comparisons were performed using paired t tests and linear regression analysis.
resultsMean PLSF, 8.27%, was greater than mean SLSF, 3.27% (p < 0.001). When categorizing patients by PLSF ranges of < 10%, 10-19.9%, and ≥ 20%, PLSF remained greater than SLSF in all subgroups (p's < 0.001). Patients with PLSF ≥ 20% had a greater absolute discrepancy with SLSF (13.31%) compared to patients with PLSF < 20% (4.74%; p < 0.0001). LSF absolute discrepancy was greater for patients with a maximum liver tumor size ≥ 5.0 cm (5.59%) compared to a liver tumor size < 5.0 cm (4.40%; p = 0.0076). For all BCLC grades and C-P scores, PLSF was greater than SLSF. A greater LSF discrepancy existed for patients with a worse C-P score (C-P A: 4.78%, C-P B/C: 6.12%; p = 0.0081), but not BCLC stage (0/A/B: 4.87%, C: 4.56%; p = 0.5993).
conclusionIn patients with HCC, SLSF is significantly lower compared to PLSF, with a greater discrepancy among patients with a PLSF ≥ 20%, tumor size ≥ 5 cm, and worse C-P score. LEVEL OF EVIDENCE: Level 3, Retrospective Study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.